Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Intracept Minimally-invasive PROcedure for VErtebrogenic Back Pain

NCT: NCT06827262 · RECRUITING

NCT IDNCT06827262
StatusRECRUITING
Start Date2025-03-26
Completion2034-07

Brief Summary

Compile real-world outcomes of commercially approved Intracept™ Intraosseous Nerve Ablation Systems in the treatment of patients diagnosed with vertebrogenic pain.

Frequently Asked Questions

What is Intracept Minimally-invasive PROcedure for VErtebrogenic Back Pain?

Intracept Minimally-invasive PROcedure for VErtebrogenic Back Pain is a clinical trial registered under NCT06827262. Current status: RECRUITING.

What is the status of NCT06827262?

The current status of NCT06827262 (Intracept Minimally-invasive PROcedure for VErtebrogenic Back Pain) is: RECRUITING.

When did Intracept Minimally-invasive PROcedure for VErtebrogenic Back Pain start?

Intracept Minimally-invasive PROcedure for VErtebrogenic Back Pain started on 2025-03-26.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑